Achilles Therapeutics PLC (STU:698)
€ 0.955 -0.005 (-0.52%) Market Cap: 39.24 Mil Enterprise Value: -45.93 Mil PE Ratio: 0 PB Ratio: 0.37 GF Score: 40/100

Achilles Therapeutics PLC SITC and Corporate Update Call Transcript

Nov 12, 2021 / 01:30PM GMT
Release Date Price: €5.65 (-1.74%)
Operator

Welcome to the Achilles Therapeutics SITC corporate update call. My name is Deborah and I will be your operator for today's call. (Operator Instructions). Please note that this conference is being recorded. I will now turn the call over to Lee Stern, Vice President Investor Relations and External Communications at Achilles. Lee, you may begin.

Lee Stern
Achilles Therapeutics plc - VP of IR & External Communications

Thank you, Deborah. We are glad you joined us for our review of today's SITC presentations and a brief corporate update. Prior to this call we issued a press release and posted a slide presentation that can be found on our website at www.achillestx.com. We will refer to this during our prepared remarks.

On today's call we have the pleasure of being joined by Dr. Samra Turajlic of the Royal Marsden's NHS Foundation Trust. Dr. Turajlic is the Chief Investigator of our THETIS clinical trial. In addition from Achilles, I am joined by Iraj Ali, our Chief Executive Officer

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot